SPOTLIGHT: Pharma sees big payback for Alzheimer's research

Pharma sees big payback for Alzheimer's research
According to The New York Times, a broad array of pharma and biotech companies are looking for new therapies to treat Alzheimer's, which is expected to claim millions of more victims as the populations of developed countries age. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.